Novo Nordisk A/S (FRA:NOV1)
Germany · Delayed Price · Currency is EUR | Market Cap | 165.91B -20.0% |
| Revenue (ttm) | 44.06B +5.6% |
| Net Income | 15.57B +4.8% |
| EPS | 3.50 +5.0% |
| Shares Out | n/a |
| PE Ratio | 10.65 |
| Forward PE | 14.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 389 |
| Open | 10.60 |
| Previous Close | 10.70 |
| Day's Range | 10.60 - 10.90 |
| 52-Week Range | 8.85 - 16.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo CEO urges staff to embrace more customer-focused culture
Novo Nordisk's CEO Mike Doustdar on Tuesday urged employees to be more customer-focused, as the Wegovy maker seeks to regain ground in the fast-growing obesity drug market.
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Novo Nordisk continues to dominate the global diabetes and obesity care markets with its portfolio of blockbuster GLP-1 therapies. Regeneron Pharmaceuticals maintains a strong foothold in ophthalmolog...
Novo Nordisk Stock (NVO) Is Falling Despite Rebrand to ‘Novo’ — Here’s Why
Novo Nordisk shares ($NVO) fell by 1% to around $43 per share early Tuesday. This came even after the popular obesity drugmaker rebranded simply to ‘ Novo ‘ on Monday.
Novo Nordisk rebranding as ‘Novo,’ announces cultural reset
Novo Nordisk (NVO) is changing its day-to-day name to “Novo” and taking a new approach to company culture, the company said on Monday. The company set out on Monday a…
Ascendis Unveils $400 Mln Buyback; Regains TransCon Rights From Novo Nordisk
(RTTNews) - Ascendis Pharma (ASND), a commercial-stage biotechnology company, said its Board has authorised a share repurchase program of up to $400 million. Separately, the company will regain exclus...
Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs
Eli Lilly on Monday said it has captured more than 30% of new patients in the U.S. market for oral obesity treatments, narrowing the early lead gained by Danish rival Novo Nordisk with its Wegovy pill...
Novo CEO talks about rebrand, corporate changes amid fight for obesity market share
Novo CEO Mike Doustdar sits down with CNBC's Annika Constantino to discuss the Danish company's rebrand and shift in corporate culture as it fights to win back obesity market share.
Novo Nordisk rebrands as 'Novo', announces cultural reset
Novo Nordisk is changing its day-to-day name to 'Novo', and taking a new approach to company culture as it looks to claw back ground in the fierce obesity drug race, the Danish drugmaker said on Mon...
Novo drops ‘Nordisk' in corporate refresh to take on Lilly in the weight-loss wars
The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
NVO: Novo Nordisk Rebrands to Capture Weight Loss Market Share
NVO: Novo Nordisk Rebrands to Capture Weight Loss Market Share
Novo Nordisk to Rebrand as Novo
The drugmaker said its new name aims to make it more recognizable to compete in the market for obesity medications.
Novo Nordisk Unveils 'Novo' Name And 'The Novo Way' Culture
(RTTNews) - Novo Nordisk A/S (NVO, NOVO-B.CO), a healthcare company, on Monday announced a rebrand centred on "Lasting Health Starts Now" and the use of "Novo" as its day-to-day name.
Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
Novo Nordisk launched its Wegovy pill in early 2026, with Eli Lilly quickly following with a pill called Foundayo. Novo Nordisk's pill has been very well received, while Eli Lilly's pill has been slow...
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
Could This New Opportunity Be Worth Billions for Novo Nordisk?
A recent clinical trial win could help Novo Nordisk expand its GLP-1 addressable market. The company is looking to bounce back after multiple setbacks.
Friday's First Moves: RH & KR Earnings Mixed, NVO Downgrade
From high-end furniture to well-known grocery stores, Diane King Hall discusses what RH (RH) and Kroger (KR) earnings say about all income brackets of American consumers. As she explains, both reports...
Novo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent Cliff
Novo Nordisk Stock Plunges on Morgan Stanley Downgrade Warns of Semaglutide Patent Cliff
Morgan Stanley Downgrades Novo Nordisk to Sell on Lilly Competition
Morgan Stanley Downgrades Novo Nordisk to Sell on Lilly Competition
Novo Nordisk Stock Falls as Morgan Stanley Doubts the Offset
Novo Nordisk Stock Falls as Morgan Stanley Doubts the Offset
Novo Nordisk Stock (NVO) Falls After Morgan Stanley’s Sell Call on Market Share Loss to Eli Lilly, Patent Cliff
Novo Nordisk shares ($NVO) fell by 2% to about $43 early Friday after Morgan Stanley Thibault Boutherin downgraded the Danish pharma giant from Hold to Sell. Boutherin said the bank’s…
Novo Nordisk downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley downgraded Novo Nordisk (NVO) to Underweight from Equal Weight with an unchanged price target of $40. The firm cites concerns over the company’s “subdued” mid-term growth and large…
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is successfully transitioning its revenue base toward newer immunology drugs to offset the loss of patent protection for Humira. Novo Nordisk maintains a dominant position in the rapidly expand...
Novo Nordisk price target raised to DKK 320 from DKK 300 at HSBC
HSBC raised the firm’s price target on Novo Nordisk (NVO) to DKK 320 from DKK 300 and keeps a Hold rating on the shares. The firm adjusted targets in the…